Trihydrophobin 1 attenuates androgen signal transduction through promoting androgen receptor degradation

Journal of Cellular Biochemistry

Volumn 109, Issue 5, 2010, Pages 1013-1024

  Yang, Yanzhong ^a   Zou, Weiying ^a   Kong, Xiangfei ^a   Wang, Hanzhou ^a   Zong, Hongliang ^a   Jiang, Jianhai ^a   Wang, Yanlin ^a   Hong, Yi ^a   Chi, Yayun ^a   Xie, Jianhui ^a   Gu, Jianxin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Androgen receptor; Degradation; Interaction; TH1; Ubiquitination

Indexed keywords

ANDROGEN RECEPTOR; CHROMOSOME PROTEIN; LIGAND; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; TRIHYDROPHOBIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL STRAIN LNCAP; CONTROLLED STUDY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANDROGENS; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; DOWN-REGULATION; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; RECEPTORS, ANDROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UBIQUITINATION;

EID: 77950380914     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22484     Document Type: Article

References (47)

1. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. 1999. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19:5143-5154.
2. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. 2006. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 5:1539-1549.
3. Bonthron DT, Hayward BE, Moran V, Strain L. 2000. Characterization of TH1 and CTSZ, two non-imprinted genes downstream of GNAS1 in chromosome 20q13. Hum Genet 107:165-175.
4. Cardozo CP, Michaud C, Ost MC, Fliss AE, Yang E, Patterson C, Hall SJ, Caplan AJ. 2003. C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch Biochem Biophys 410:134-140.
5. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 1993. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
6. Darne C, Veyssiere G, Jean C. 1998. Phorbol ester causes ligand-independent activation of the androgen receptor. Eur J Biochem 256:541-549.
7. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el N. 2003. Androgen-independent prostate cancer: Potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 5:99-109.
8. Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. 2005. Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 146:1707-1712.
9. Gaughan L, Logan IR, Neal DE, Robson CN. 2005. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33:13-26.
10. Hari KL, Santerre A, Sekelsky JJ, McKim KS, Boyd JB, Hawley RS. 1995. The mei-41 gene of D. melanogaster is a structural and functional homolog of the human ataxia telangiectasia gene. Cell 82:815-821.
11. He B, Bai S, Hnat AT, Kalman RI, Minges JT, Patterson C, Wilson EM. 2004. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem 279: 30643-30653.
12. Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S, Pimplikar SW, Chang C. 2005. Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol Endocrinol 19:350-361.
13. Jaworski T. 2006. Degradation and beyond: Control of androgen receptor activity by the proteasome system. Cell Mol Biol Lett 11:109-131.
14. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. 1991. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-1404.
15. Kang HY, Yeh S, Fujimoto N, Chang C. 1999. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570-8576.
16. Koivisto P, Visakorpi T, Kallioniemi OP. 1996. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 226:57-63.
17. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. 2007. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 67:9001-9005.
18. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. 2002. Phosphorylation- dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21:4037-4048.
19. Liu W, Shen X, Yang Y, Yin X, Xie J, Yan J, Jiang J, Liu W, Wang H, Sun M, Zheng Y, Gu J. 2004. Trihydrophobin 1 is a new negative regulator of A-Raf kinase. J Biol Chem 279:10167-10175.
20. MacLean HE, Warne GL, Zajac JD. 1997. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 62:233-242.
21. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. 1995. The nuclear receptor superfamily: The second decade. Cell 83:835-839.
22. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, Milburn MV, Glass CK, Rosenfeld MG. 1998. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 12:3357-3368.
23. Montie JE, Pienta KJ. 1994. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 43:892-899.
24. Narita T, Yamaguchi Y, Yano K, Sugimoto S, Chanarat S, Wada T, Kim DK, Hasegawa J, Omori M, Inukai N, Endoh M, Yamada T, Handa H. 2003. Human transcription elongation factor NELF: Identification of novel subunits and reconstitution of the functionally active complex. Mol Cell Biol 23:1863-1873.
25. Nazareth LV, Weigel NL. 1996. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907.
26. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357.
27. Pajonk F, Ophoven AV, McBride WH. 2005. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res 65:4836-4843.
28. Poukka H, Karvonen U, Yoshikawa N, Tanaka H, Palvimo JJ, Janne OA. 2000. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci 113(Pt 17):2991-3001.
29. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. 1995. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr Rev 16:271-321.
30. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. 1998. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 58:4497-4504.
31. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
32. Sheflin L, Keegan B, Zhang W, Spaulding SW. 2000. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276:144-150.
33. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. 1990a. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540.
34. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HC, Trapman J, Mulder E. 1990b. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1052:187-194.
35. Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P, Chang C. 2004. Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Mol Cell Biol 24: 2202-2213.
36. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
37. Wong CI, Zhou ZX, Sar M, Wilson EM. 1993. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem 268:19004-19012.
38. Wu CH, Yamaguchi Y, Benjamin LR, Horvat-Gordon M, Washinsky J, Enerly E, Larsson J, Lambertsson A, Handa H, Gilmour D. 2003. NELF and DSIF cause promoter proximal pausing on the hsp70 promoter in Drosophila. Genes Dev 17:1402-1414.
39. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H. 1999. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 97:41-51.
40. Yang Y, Liu W, Zou W, Wang H, Zong H, Jiang J, Wang Y, Gu J. 2007. Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). J Cell Biochem 101:167-180.
41. Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. 2008. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol 217:569-576.
42. Yeh S, Chang C. 1996. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-5521.
43. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463.
44. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C. 2000. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 97:11256-11261.
45. Yin XL, Chen S, Gu JX. 2002. Identification of TH1 as an interaction partner of A-Raf kinase. Mol Cell Biochem 231:69-74.
46. Zhang Y, Yang Y, Yeh S, Chang C. 2004. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol 24: 1044-1057.
47. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. 1995. Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-218.